StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

Edgewise Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Edgewise Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$158.38M. For fiscal 2025 it was -$143.82M. The highest annual figure on record is -$14.63M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$143.82M–
FY2024Dec 31, 2024-$109.03M–
FY2023Dec 31, 2023-$91.95M–
FY2022Dec 31, 2022-$52.64M–
FY2021Dec 31, 2021-$33.51M–
FY2020Dec 31, 2020-$14.63M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.47M–
Q1 FY2026Mar 31, 2026-$42.54M–
Q4 FY2025Dec 31, 2025-$38.59M–
Q3 FY2025Sep 30, 2025-$34.78M–
Q2 FY2025Jun 30, 2025-$32.58M–
Q1 FY2025Mar 31, 2025-$37.87M–
Q4 FY2024Dec 31, 2024-$26.96M–
Q3 FY2024Sep 30, 2024-$27.37M–
Q2 FY2024Jun 30, 2024-$26.10M–
Q1 FY2024Mar 31, 2024-$28.60M–
Q4 FY2023Dec 31, 2023-$26.83M–
Q3 FY2023Sep 30, 2023-$22.06M–
Q2 FY2023Jun 30, 2023-$20.23M–
Q1 FY2023Mar 31, 2023-$22.83M–
Q4 FY2022Dec 31, 2022-$11.86M–
Q3 FY2022Sep 30, 2022-$11.96M–
Q2 FY2022Jun 30, 2022-$16.25M–
Q1 FY2022Mar 31, 2022-$12.57M–
Q4 FY2021Dec 31, 2021-$9.42M–
Q3 FY2021Sep 30, 2021-$8.26M–
Q2 FY2021Jun 30, 2021-$9.77M–
Q1 FY2021Mar 31, 2021-$6.06M–
Q4 FY2020Dec 31, 2020-$4.64M–
Q3 FY2020Sep 30, 2020-$3.27M–
Q2 FY2020Jun 30, 2020-$3.99M–
Q1 FY2020Mar 31, 2020-$2.74M–

More Edgewise Therapeutics figures

See a number that looks wrong?